| Primary |
| Product Used For Unknown Indication |
60.1% |
| Drug Use For Unknown Indication |
7.2% |
| Fungal Infection |
5.3% |
| Bronchopulmonary Aspergillosis |
4.2% |
| Visceral Leishmaniasis |
3.1% |
| Aspergillosis |
2.0% |
| Zygomycosis |
1.9% |
| Prophylaxis |
1.8% |
| Meningitis Cryptococcal |
1.7% |
| Febrile Neutropenia |
1.6% |
| Pneumonia |
1.4% |
| Systemic Candida |
1.4% |
| Acute Myeloid Leukaemia |
1.3% |
| Sedation |
1.2% |
| Candidiasis |
1.0% |
| Systemic Mycosis |
1.0% |
| Cryptococcosis |
1.0% |
| Infection |
1.0% |
| Pyrexia |
0.9% |
| Sepsis |
0.9% |
|
| Rhabdomyolysis |
12.9% |
| Drug Ineffective |
12.4% |
| Death |
10.4% |
| Off Label Use |
6.3% |
| Hypokalaemia |
5.6% |
| White Blood Cell Count Decreased |
5.4% |
| Renal Impairment |
4.8% |
| Renal Failure |
4.6% |
| Respiratory Failure |
4.4% |
| Sepsis |
4.4% |
| Renal Failure Acute |
4.1% |
| Pyrexia |
3.7% |
| Drug Ineffective For Unapproved Indication |
3.2% |
| Pancytopenia |
3.2% |
| Shock |
2.9% |
| Renal Disorder |
2.7% |
| Ventricular Fibrillation |
2.4% |
| Vomiting |
2.4% |
| Interstitial Lung Disease |
2.0% |
| Tachycardia |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
43.3% |
| Prophylaxis |
7.2% |
| Drug Use For Unknown Indication |
5.5% |
| Pneumonia |
4.4% |
| Fungal Infection |
3.7% |
| Infection |
3.6% |
| Acute Myeloid Leukaemia |
3.0% |
| Sedation |
3.0% |
| Myelodysplastic Syndrome |
2.9% |
| Ureteral Stent Insertion |
2.8% |
| Ureteral Stent Removal |
2.8% |
| Fluid Replacement |
2.5% |
| Insomnia |
2.2% |
| Sepsis |
2.1% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Bronchopulmonary Aspergillosis |
2.0% |
| Infection Prophylaxis |
1.9% |
| Pyrexia |
1.8% |
| Hypertension |
1.8% |
| Febrile Neutropenia |
1.6% |
|
| Renal Impairment |
14.2% |
| Off Label Use |
10.2% |
| Renal Failure |
7.3% |
| Respiratory Failure |
6.9% |
| Toxic Epidermal Necrolysis |
6.9% |
| Renal Failure Acute |
6.3% |
| Drug Ineffective |
4.3% |
| Rhabdomyolysis |
4.3% |
| Platelet Count Increased |
4.0% |
| Pancreatitis Acute |
3.6% |
| Thrombocytopenia |
3.6% |
| Blood Alkaline Phosphatase Increased |
3.3% |
| Cholestasis |
3.3% |
| Hypokalaemia |
3.3% |
| Renal Disorder |
3.3% |
| Staphylococcal Infection |
3.3% |
| Transfusion |
3.3% |
| Vomiting |
3.0% |
| Weight Increased |
3.0% |
| Anaphylactic Reaction |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.3% |
| Drug Use For Unknown Indication |
18.8% |
| Acute Myeloid Leukaemia |
12.0% |
| Prophylaxis |
8.5% |
| Infection |
4.0% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Antifungal Prophylaxis |
3.3% |
| Multiple Myeloma |
3.3% |
| Nausea |
2.9% |
| Febrile Neutropenia |
2.7% |
| Myelodysplastic Syndrome |
2.4% |
| Allogenic Bone Marrow Transplantation Therapy |
2.3% |
| Bronchopulmonary Aspergillosis |
2.2% |
| Sepsis |
2.2% |
| Pneumonia |
1.9% |
| Immunosuppression |
1.9% |
| Hiv Infection |
1.8% |
| Hypertension |
1.8% |
| Infection Prophylaxis |
1.6% |
| Fungal Infection |
1.5% |
|
| Sepsis |
13.9% |
| Thrombocytopenia |
9.7% |
| Septic Shock |
9.4% |
| Pneumonia |
7.7% |
| White Blood Cell Count Decreased |
7.1% |
| Renal Failure |
5.8% |
| Pyrexia |
5.2% |
| Venous Stent Insertion |
5.2% |
| Vomiting |
4.2% |
| Renal Impairment |
3.9% |
| Febrile Neutropenia |
3.5% |
| Respiratory Failure |
3.2% |
| Venoocclusive Liver Disease |
3.2% |
| Weight Increased |
3.2% |
| Death |
2.9% |
| Platelet Count Decreased |
2.6% |
| Rectal Haemorrhage |
2.6% |
| Tachycardia |
2.6% |
| Renal Failure Acute |
2.3% |
| Drug Ineffective |
1.9% |
|
| Interacting |
| Product Used For Unknown Indication |
59.9% |
| Zygomycosis |
5.1% |
| Acute Promyelocytic Leukaemia |
4.5% |
| Pulmonary Mycosis |
4.5% |
| Hyperglycaemia |
3.2% |
| Bacterial Infection |
2.5% |
| Febrile Neutropenia |
2.5% |
| Fungal Infection |
2.5% |
| Neutrophil Count Decreased |
2.5% |
| Pain |
2.5% |
| Pneumonia |
2.5% |
| Pneumonia Fungal |
2.5% |
| Chronic Granulomatous Disease |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
| Type 1 Diabetes Mellitus |
1.3% |
| Infection |
0.6% |
| Tumour Associated Fever |
0.6% |
|
| Torsade De Pointes |
22.6% |
| Myoclonic Epilepsy |
19.4% |
| Drug Interaction |
16.1% |
| Hypokalaemia |
12.9% |
| Myositis |
6.5% |
| Pulmonary Haemorrhage |
6.5% |
| Treatment Noncompliance |
6.5% |
| Blood Creatinine Increased |
3.2% |
| Cardiac Failure |
3.2% |
| Hepatic Function Abnormal |
3.2% |
|
